Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Yissum Presents Promising Pre-Clinical Results for Oral Delivery of the Anti-Cancer Drug Docetaxel Using a Novel Nanotechnology Approach: Findings published in the prestigious journal "Cancer Research"

Abstract:
Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today successful pre-clinical data of oral delivery of Docetaxel, an anti-cancer drug, utilizing a novel nanotechnology platform. The technology, invented by Professor Simon Benita, Head of Institute for Drug Research, the School of Pharmacy, Faculty of Medicine at the Hebrew University, enables controlled drug release and increased bioavailability of orally administered lipophilic drugs. The findings were published by the prestigious Cancer Research journal (cancerres.aacrjournals.org/content/early/2011/02/25/0008-5472.CAN-10-3118.abstract).

Yissum Presents Promising Pre-Clinical Results for Oral Delivery of the Anti-Cancer Drug Docetaxel Using a Novel Nanotechnology Approach: Findings published in the prestigious journal "Cancer Research"

Jerusalem, Israel | Posted on April 12th, 2011

Oral administration of lipophilic drugs is particularly challenging because they are both metabolized and actively expelled from the intestine. One of the main culprits is a protein pump called P-glycoprotein that transports the drugs back into the intestinal lumen after they have been absorbed into the body. One such lipophilic drug is Docetaxel, an anticancer drug widely prescribed for the treatment of various types of solid tumor cancer. Docetaxel is poorly soluble in water and vigorously pumped out of the intestine wall cells by P-glycoprotein. Therefore, this drug is delivered solely by intravenous infusion, after being solubilized by surfactants, which often increase adverse side effects. The innovative drug delivery technology involves the formation of drug nano-capsules that are then packed in microparticles in a manner that prevents metabolism and expulsion of the drug from the gut. The result is enhanced oral bioavailability along with prolonged release of the drug.

The data of the pre-clinical trials performed on rodents showed that the oral bioavailability of the drug embedded in the novel microparticles was 10 to 20 fold higher than other oral delivery methods, and the levels of the drug were high in the blood stream. Despite the high blood levels achieved, the rats did not suffer from immediate side effects, indicating that the drug did not interact with the gut mucosal tissue. The anti-cancer activity of the novel formulation was demonstrated in cell cultures.

In June 2009, Yissum signed a collaborative agreement with Aurum Ventures MKI, the technology investment arm of Mr. Morris Kahn, for the further development of this oral drug delivery platform.

"Docetaxel is used for the treatment of a variety of cancers, and is currently administered as a high dose infusion every three weeks, resulting in side effects that could be quite severe," said Yaacov Michlin, CEO of Yissum. "Patients in need of this drug will thus greatly benefit from the ability to receive the drug in lower doses using an oral route. The recently published preclinical trials show that Prof. Benita's invention, currently being developed by Aurum Ventures MKI, has a real potential to offer cancer patients an oral delivery route for Docetaxel. The new delivery platform has been previously shown to be effective also for other drugs, and offers a revolutionary method to bypass specific potent barriers in the intestine and the liver, thereby greatly increasing bioavailability."

Prof. Benita added, "This unique system may allow changing the route of administration of highly lipophilic P-glycoprotein substrate drugs from injectable to oral with potentially high bioavailability and lower side effects without affecting the normal physiological activity of the metabolic filters."

####

About Yissum Research Development Company Ltd.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Products based on Hebrew University technologies that have been commercialized by Yissum currently generate $1.2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered 6100 patents covering 1750 inventions; has licensed out 480 technologies and has spun out 65 companies. Yissum’s business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more.

About Aurum

Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent business man, philanthropist and entrepreneur. Aurum Ventures MKI invests in Israeli and Israel related companies in the fields of life sciences and clean-tech in all stages of development. For further information please visit www.aurum.co.il.

For more information, please click here

Contacts:
Yissum Ltd.
Tsipi Haitovsky, Media Liaison
+972-52-598-9892

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Nanomedicine

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Discoveries

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Announcements

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Patents/IP/Tech Transfer/Licensing

Silvaco, Purdue team up to bring scalable atomistic TCAD solutions for next generation semiconductor devices and materials August 24th, 2018

CTI Materials drives nano commercialization with it's patented surfactant free nanoparticle dispersions August 15th, 2018

Sirrus's Issued Patent Portfolio Continues To Accelerate July 18th, 2018

Changing the grocery game: Manufacturing process provides low-cost, sustainable option for food packaging June 26th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project